$CYDY The safety profile of Leron, along with its efficacy in restoring homeostasis are the key driving factors in assuring their CD12 will be statistically significant. When you factor in Remfesivir being given to patients to severe or critically ill patients and are associated with renal and liver toxicitities? that ONLY HELPED LERONLIMAB. NOT to mention poor cardiac functioning associated with COVID fibrosis. Now, if you don't believe me, go ask why did BCRX's Galidesivir was discontinued in Brazil for the Phase I trial❓It is simple. Safety concerns or serious adverse events resulting in higher deaths. Galidesivir is the 2.0 version of Remdesivir. A nucleotide inhibitor that has similar mechanisms of action to Gilead 's Remdesivir. No clinical benefit. At all. πŸƒπŸƒπŸƒπŸƒπŸƒ
  • 9
9 Likes